Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache
Abstract Background CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache. Methods Patients (N = 164) received galcanezumab 300 mg subcutaneousl...
Saved in:
| Published in | Cephalalgia Vol. 42; no. 11-12; pp. 1225 - 1235 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London, England
SAGE Publications
01.10.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract
Background
CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache.
Methods
Patients (N = 164) received galcanezumab 300 mg subcutaneously up to once a month. Primary endpoint was safety, as assessed by treatment-emergent adverse events, serious adverse events, and suicidality. Other endpoints included discontinuation rates, immunogenicity, efficacy as assessed by the Patient Global Impression of Improvement, and health values.
Results
At baseline, mean (standard deviation) age was 48.3 (9.8) years, 75.0% were men, and 85.4% were white. Treatment-emergent adverse events (n = 119 [72.6%]) were mostly mild-to-moderate, with nasopharyngitis the most commonly reported (22.0%). One of 18 serious adverse events was judged as treatment related (constipation). Two patients (1.2%) reported suicidal ideation. Five patients (3.1%) discontinued due to an adverse event. Eight patients were treatment-emergent anti-drug antibody positive, two of whom were not treatment-emergent anti-drug antibody positive in the parent studies. On the Patient Global Impression of Improvement, ≥81% reported their cluster headache status as very much, much, or a little better at Months 1, 6, and 12. Health value scores generally improved from baseline.
Conclusions
In this open-label study, galcanezumab was generally well tolerated and improved patient-reported cluster headache status.
Trial registration number: NCT02797951; https://clinicaltrials.gov/ct2/show/NCT02797951 |
|---|---|
| AbstractList | CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache.BACKGROUNDCGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache.Patients (N = 164) received galcanezumab 300 mg subcutaneously up to once a month. Primary endpoint was safety, as assessed by treatment-emergent adverse events, serious adverse events, and suicidality. Other endpoints included discontinuation rates, immunogenicity, efficacy as assessed by the Patient Global Impression of Improvement, and health values.METHODSPatients (N = 164) received galcanezumab 300 mg subcutaneously up to once a month. Primary endpoint was safety, as assessed by treatment-emergent adverse events, serious adverse events, and suicidality. Other endpoints included discontinuation rates, immunogenicity, efficacy as assessed by the Patient Global Impression of Improvement, and health values.At baseline, mean (standard deviation) age was 48.3 (9.8) years, 75.0% were men, and 85.4% were white. Treatment-emergent adverse events (n = 119 [72.6%]) were mostly mild-to-moderate, with nasopharyngitis the most commonly reported (22.0%). One of 18 serious adverse events was judged as treatment related (constipation). Two patients (1.2%) reported suicidal ideation. Five patients (3.1%) discontinued due to an adverse event. Eight patients were treatment-emergent anti-drug antibody positive, two of whom were not treatment-emergent anti-drug antibody positive in the parent studies. On the Patient Global Impression of Improvement, ≥81% reported their cluster headache status as very much, much, or a little better at Months 1, 6, and 12. Health value scores generally improved from baseline.RESULTSAt baseline, mean (standard deviation) age was 48.3 (9.8) years, 75.0% were men, and 85.4% were white. Treatment-emergent adverse events (n = 119 [72.6%]) were mostly mild-to-moderate, with nasopharyngitis the most commonly reported (22.0%). One of 18 serious adverse events was judged as treatment related (constipation). Two patients (1.2%) reported suicidal ideation. Five patients (3.1%) discontinued due to an adverse event. Eight patients were treatment-emergent anti-drug antibody positive, two of whom were not treatment-emergent anti-drug antibody positive in the parent studies. On the Patient Global Impression of Improvement, ≥81% reported their cluster headache status as very much, much, or a little better at Months 1, 6, and 12. Health value scores generally improved from baseline.In this open-label study, galcanezumab was generally well tolerated and improved patient-reported cluster headache status.Trial registration number: NCT02797951; https://clinicaltrials.gov/ct2/show/NCT02797951.CONCLUSIONSIn this open-label study, galcanezumab was generally well tolerated and improved patient-reported cluster headache status.Trial registration number: NCT02797951; https://clinicaltrials.gov/ct2/show/NCT02797951. CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache. Patients (N = 164) received galcanezumab 300 mg subcutaneously up to once a month. Primary endpoint was safety, as assessed by treatment-emergent adverse events, serious adverse events, and suicidality. Other endpoints included discontinuation rates, immunogenicity, efficacy as assessed by the Patient Global Impression of Improvement, and health values. At baseline, mean (standard deviation) age was 48.3 (9.8) years, 75.0% were men, and 85.4% were white. Treatment-emergent adverse events (n = 119 [72.6%]) were mostly mild-to-moderate, with nasopharyngitis the most commonly reported (22.0%). One of 18 serious adverse events was judged as treatment related (constipation). Two patients (1.2%) reported suicidal ideation. Five patients (3.1%) discontinued due to an adverse event. Eight patients were treatment-emergent anti-drug antibody positive, two of whom were not treatment-emergent anti-drug antibody positive in the parent studies. On the Patient Global Impression of Improvement, ≥81% reported their cluster headache status as very much, much, or a little better at Months 1, 6, and 12. Health value scores generally improved from baseline. In this open-label study, galcanezumab was generally well tolerated and improved patient-reported cluster headache status. NCT02797951; https://clinicaltrials.gov/ct2/show/NCT02797951. Abstract Background CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3 double-blind studies in chronic or episodic cluster headache. Methods Patients (N = 164) received galcanezumab 300 mg subcutaneously up to once a month. Primary endpoint was safety, as assessed by treatment-emergent adverse events, serious adverse events, and suicidality. Other endpoints included discontinuation rates, immunogenicity, efficacy as assessed by the Patient Global Impression of Improvement, and health values. Results At baseline, mean (standard deviation) age was 48.3 (9.8) years, 75.0% were men, and 85.4% were white. Treatment-emergent adverse events (n = 119 [72.6%]) were mostly mild-to-moderate, with nasopharyngitis the most commonly reported (22.0%). One of 18 serious adverse events was judged as treatment related (constipation). Two patients (1.2%) reported suicidal ideation. Five patients (3.1%) discontinued due to an adverse event. Eight patients were treatment-emergent anti-drug antibody positive, two of whom were not treatment-emergent anti-drug antibody positive in the parent studies. On the Patient Global Impression of Improvement, ≥81% reported their cluster headache status as very much, much, or a little better at Months 1, 6, and 12. Health value scores generally improved from baseline. Conclusions In this open-label study, galcanezumab was generally well tolerated and improved patient-reported cluster headache status. Trial registration number: NCT02797951; https://clinicaltrials.gov/ct2/show/NCT02797951 |
| Author | Riesenberg, Robert Stroud, Chad E Dong, Yan Bangs, Mark E Wenzel, Richard Martinez, James M Oakes, Tina Myers Gaul, Charly |
| Author_xml | – sequence: 1 givenname: Robert surname: Riesenberg fullname: Riesenberg, Robert organization: Atlanta Center for Medical Research, Atlanta, United States – sequence: 2 givenname: Charly surname: Gaul fullname: Gaul, Charly organization: Headache Center, Frankfurt, Germany – sequence: 3 givenname: Chad E surname: Stroud fullname: Stroud, Chad E organization: Eli Lilly and Company, Indianapolis, Indiana, United States – sequence: 4 givenname: Yan surname: Dong fullname: Dong, Yan organization: Eli Lilly and Company, Indianapolis, Indiana, United States – sequence: 5 givenname: Mark E surname: Bangs fullname: Bangs, Mark E organization: Eli Lilly and Company, Indianapolis, Indiana, United States – sequence: 6 givenname: Richard surname: Wenzel fullname: Wenzel, Richard organization: Eli Lilly and Company, Indianapolis, Indiana, United States – sequence: 7 givenname: James M surname: Martinez fullname: Martinez, James M organization: Eli Lilly and Company, Indianapolis, Indiana, United States – sequence: 8 givenname: Tina Myers surname: Oakes fullname: Oakes, Tina Myers email: t_oakes@lilly.com organization: Eli Lilly and Company, Indianapolis, Indiana, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35633025$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1r3DAQhkVISTZpfkAvRcdcnOrD8sexhHwUFnpJzmYsj3a12JIryZTtr6-W3eTQQg6DBvQ8w_DOFTl33iEhXzi747yuvzEpJWeiFIJzJhVrz8iKl1VTiLYR52R1-C8OwCW5inHHGFMVqy7IpVSVlEyoFdmsvdsUCcNE_YyuGKHHkUYwmPY0pmXYU2_oBkYNDv8sE_TUOjpDsuhSpL9t2lKcbfSD1dQHqrfBu9zqcYl5Kt0iDKC3-Jl8MjBGvDm91-T18eHl_rlY_3z6cf99XWhZslTU0gxCSwUSkTcSsMfWgFKcGWyxZWXFoJKGYyOUgl6oulS6HYypG96LXshrcnucOwf_a8GYuslGjeOY1_dL7ERV81yirDL69YQu_YRDNwc7Qdh3b-FkgB8BHXyMAc07wll3OED33wGyU__jaJtyWt6lAHb80Lw7mhE22O38ElwO6gPhLxJ4lgI |
| CitedBy_id | crossref_primary_10_3390_medicina61030437 crossref_primary_10_1001_jamaneurol_2022_4804 crossref_primary_10_7326_ANNALS_24_00551 crossref_primary_10_1212_CON_0000000000001411 crossref_primary_10_1111_ene_15956 crossref_primary_10_1055_a_2123_7121 crossref_primary_10_1007_s11096_024_01758_2 crossref_primary_10_1186_s10194_023_01661_7 crossref_primary_10_1007_s40122_024_00674_7 crossref_primary_10_1007_s42399_023_01452_w |
| Cites_doi | 10.1186/s12883-020-1609-7 10.1177/0333102417738202 10.1097/WCO.0000000000000680 10.2147/JPR.S305066 10.1056/NEJMoa1813440 10.1176/appi.ajp.2011.10111704 10.1038/bjp.2008.334 10.1111/head.14011 10.1111/j.1468-2982.2008.01592.x 10.1007/s11136-011-9903-x 10.1111/head.14234 10.1177/0333102420905321 10.1111/j.1742-7843.2004.pto940606.x 10.1016/j.npep.2010.12.002 10.1152/physrev.00034.2013 10.1177/0333102413485658 10.1016/0168-8510(90)90421-9 |
| ContentType | Journal Article |
| Copyright | International Headache Society 2022 |
| Copyright_xml | – notice: International Headache Society 2022 |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1177/03331024221103509 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-2982 |
| EndPage | 1235 |
| ExternalDocumentID | 35633025 10_1177_03331024221103509 10.1177_03331024221103509 |
| Genre | Journal Article |
| GroupedDBID | --- -TM .2F .2G .3N .GJ .Y3 01A 0R~ 1OC 29B 31S 31T 31Y 31~ 36B 4.4 53G 54M 5GY 5RE 5VS 6PF 8-1 AABMB AABOD AACKU AADUE AAGGD AAHHS AAJIQ AAJOX AAJPV AANSI AAPEO AAQDB AAQXH AARDL AARIX AASGM AAWTL AAXOT AAYTG AAZBJ ABAWC ABAWP ABCCA ABCQN ABDBF ABDWY ABEIX ABFWQ ABHKI ABIVO ABJIS ABJNI ABKRH ABNCE ABPGX ABQKF ABQXT ABRHV ABVFX ABVVC ABYTW ACARO ACCFJ ACDSZ ACDXX ACFMA ACFYK ACGBL ACGFS ACLHI ACNXM ACOFE ACROE ACRPL ACUHS ACXQS ADBBV ADEBD ADEIA ADMPF ADNBR ADNMO ADOGD ADSTG ADTBJ ADUKL ADYCS ADZOD ADZYD ADZZY AECVZ AEEZP AENEX AEQDE AEQLS AERKM AEUHG AEWDL AEXFG AEXNY AFBPY AFCOW AFEBI AFEET AFKBI AFKRG AFRWT AFUIA AFVCE AFWMB AFZJQ AGNHF AGQPQ AHEFC AIGRN AIWBW AJABX AJAOE AJBDE AJEFB AJMMQ AJSCY AJUZI AJXGE ALMA_UNASSIGNED_HOLDINGS ARTOV ASPBG AUTPY AVWKF AYAKG AZFZN B8M B8O B93 BDDNI BFHJK BKSCU BSEHC BYIEH CAG CBRKF CDWPY CFDXU CO8 COF CORYS CQQTX CS3 CUTAK DC- DC. DC0 DC6 DCZOG DD- DD0 DE- DOPDO DU5 D~Y EAD EAP EAS EBC EBD EBS EBX ECV EJD EMB EMK EMOBN ENC EPT ESX F5P FEDTE FZ0 GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HVGLF HZI HZ~ IHE J8X K.F K.J LH4 LW6 N9A O9- OIG OVD P.B P2P Q1R Q7K Q7R Q7X Q82 Q~Q ROL S01 SASJQ SAUOL SCDPB SCNPE SFC SV3 TEORI TUS W99 WYUIH YFH ZGI ZONMY ZPPRI ZRKOI ZSSAH AAYXX ACHEB CITATION 31X AAMGE AATBZ ACGZU ACSIQ ACTQU ACUIR AEUIJ AEWHI AIOMO B8Z DV7 M4V NPM 7X8 |
| ID | FETCH-LOGICAL-c340t-73fd2c35a3ee183aebe9fa5510fe9e90460a63f1e8255ab25745c9dff781b2b23 |
| IEDL.DBID | AFRWT |
| ISSN | 0333-1024 1468-2982 |
| IngestDate | Thu Jul 10 22:19:04 EDT 2025 Wed Feb 19 02:26:16 EST 2025 Thu Apr 24 23:04:44 EDT 2025 Tue Jul 01 05:21:25 EDT 2025 Tue Jun 17 22:29:33 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11-12 |
| Keywords | Cluster headache pain central nervous system disease CGRP galcanezumab headache disorder |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c340t-73fd2c35a3ee183aebe9fa5510fe9e90460a63f1e8255ab25745c9dff781b2b23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 35633025 |
| PQID | 2671267246 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2671267246 pubmed_primary_35633025 crossref_primary_10_1177_03331024221103509 crossref_citationtrail_10_1177_03331024221103509 sage_journals_10_1177_03331024221103509 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-01 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London, England |
| PublicationPlace_xml | – name: London, England – name: England |
| PublicationTitle | Cephalalgia |
| PublicationTitleAlternate | Cephalalgia |
| PublicationYear | 2022 |
| Publisher | SAGE Publications |
| Publisher_xml | – name: SAGE Publications |
| References | Lasaosa, Diago, Calzada 2017; 18 Andrews, Kudrow, Rettiganti 2021; 14 Posner, Brown, Stanley 2011; 168 Bangs, Kudrow, Wang 2020; 20 Fischera, Marziniak, Gralow 2008; 28 Láinez, Schoenen, Stroud 2022; 62 Arulmani, Schuijt, Heiligers 2004; 94 1990; 16 Zeller, Poulsen, Sutton 2008; 155 Lund, Snoer, Jensen 2019; 32 Goadsby, Dodick, Leone 2019; 381 Russell, King, Smillie 2014; 94 Kudrow, Andrews, Rettiganti 2020; 60 Dodick, Goadsby, Lucas 2020; 40 Smillie, Brain 2011; 45 Herdman, Gudex, Lloyd 2011; 20 Guy 1976 bibr14-03331024221103509 bibr8-03331024221103509 Lasaosa SS (bibr17-03331024221103509) 2017; 18 bibr20-03331024221103509 bibr5-03331024221103509 bibr11-03331024221103509 bibr1-03331024221103509 bibr4-03331024221103509 bibr18-03331024221103509 bibr2-03331024221103509 bibr7-03331024221103509 Guy W. (bibr9-03331024221103509) 1976 bibr15-03331024221103509 bibr3-03331024221103509 bibr19-03331024221103509 bibr12-03331024221103509 bibr13-03331024221103509 bibr10-03331024221103509 bibr6-03331024221103509 bibr16-03331024221103509 |
| References_xml | – volume: 45 start-page: 93 year: 2011 end-page: 104 article-title: Calcitonin gene-related peptide (CGRP) and its role in hypertension publication-title: Neuropeptides – volume: 94 start-page: 291 year: 2004 end-page: 297 article-title: Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats publication-title: Basic Clin Pharmacol Toxicol – volume: 40 start-page: 935 year: 2020 end-page: 948 article-title: Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment publication-title: Cephalalgia – volume: 60 start-page: 2254 year: 2020 end-page: 2264 article-title: Treatment outcomes in patients treated with galcanezumab vs placebo: Post hoc analyses from a phase 3 randomized study in patients with episodic cluster headache publication-title: Headache – volume: 16 start-page: 199 year: 1990 end-page: 208 article-title: EuroQol–a new facility for the measurement of health-related quality of life publication-title: Health Policy – volume: 20 start-page: 25 year: 2020 article-title: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies publication-title: BMC Neurol – volume: 94 start-page: 1099 year: 2014 end-page: 1142 article-title: Calcitonin gene-related peptide: physiology and pathophysiology publication-title: Physiol Rev – volume: 381 start-page: 132 year: 2019 end-page: 141 article-title: Trial of galcanezumab in prevention of episodic cluster headache publication-title: N Engl J Med – volume: 18 start-page: 1161 year: 2017 end-page: 1167 article-title: . Cardiovascular risk factors in cluster headache publication-title: Pain Med – year: 1976 article-title: ECDEU assessment manual for psychopharmacology, revised 1976. Rockville, MD publication-title: National Institute of Mental Health, Psychopharmacology Research Branch – volume: 20 start-page: 1727 year: 2011 end-page: 1736 article-title: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) publication-title: Qual Life Res – volume: 32 start-page: 443 year: 2019 end-page: 448 article-title: The influence of lifestyle and gender on cluster headache publication-title: Curr Opin Neurol – volume: 155 start-page: 1093 year: 2008 end-page: 1103 article-title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat publication-title: Br J Pharmacol – volume: 168 start-page: 1266 year: 2011 end-page: 1277 article-title: The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults publication-title: Am J Psychiatry – volume: 28 start-page: 614 year: 2008 end-page: 618 article-title: The incidence and prevalence of cluster headache: a meta-analysis of population-based studies publication-title: Cephalalgia – volume: 62 start-page: 65 year: 2022 end-page: 77 article-title: Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment publication-title: Headache – volume: 14 start-page: 2059 year: 2021 end-page: 2070 article-title: Impact of galcanezumab on total pain burden: A post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study in patients with episodic cluster headache publication-title: J Pain Res – ident: bibr12-03331024221103509 doi: 10.1186/s12883-020-1609-7 – ident: bibr1-03331024221103509 doi: 10.1177/0333102417738202 – ident: bibr18-03331024221103509 doi: 10.1097/WCO.0000000000000680 – ident: bibr19-03331024221103509 doi: 10.2147/JPR.S305066 – ident: bibr5-03331024221103509 doi: 10.1056/NEJMoa1813440 – ident: bibr8-03331024221103509 doi: 10.1176/appi.ajp.2011.10111704 – year: 1976 ident: bibr9-03331024221103509 publication-title: National Institute of Mental Health, Psychopharmacology Research Branch – ident: bibr14-03331024221103509 doi: 10.1038/bjp.2008.334 – ident: bibr20-03331024221103509 doi: 10.1111/head.14011 – ident: bibr7-03331024221103509 – ident: bibr2-03331024221103509 doi: 10.1111/j.1468-2982.2008.01592.x – ident: bibr11-03331024221103509 doi: 10.1007/s11136-011-9903-x – ident: bibr6-03331024221103509 doi: 10.1111/head.14234 – ident: bibr4-03331024221103509 doi: 10.1177/0333102420905321 – ident: bibr13-03331024221103509 doi: 10.1111/j.1742-7843.2004.pto940606.x – ident: bibr16-03331024221103509 doi: 10.1016/j.npep.2010.12.002 – volume: 18 start-page: 1161 year: 2017 ident: bibr17-03331024221103509 publication-title: Pain Med – ident: bibr15-03331024221103509 doi: 10.1152/physrev.00034.2013 – ident: bibr3-03331024221103509 doi: 10.1177/0333102413485658 – ident: bibr10-03331024221103509 doi: 10.1016/0168-8510(90)90421-9 |
| SSID | ssj0005606 |
| Score | 2.4207175 |
| Snippet | Abstract
Background
CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of... CGAR, a Phase 3b open-label study, evaluated the long-term safety of galcanezumab in patients with cluster headache who completed one of two Phase 3... |
| SourceID | proquest pubmed crossref sage |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1225 |
| Title | Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache |
| URI | https://journals.sagepub.com/doi/full/10.1177/03331024221103509 https://www.ncbi.nlm.nih.gov/pubmed/35633025 https://www.proquest.com/docview/2671267246 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NS-QwFH-4Iyx7ET921_GLCAvCQtY2aZP2JH4NIqsHUdZbSTuJCDOt2Pagf73vTVPF3VU89FLaJLzv5L38HsAPmbrUxUnI0fvlHA1ewBOlLB8nhda50pEK6e7w2bk6uYpOr-PrOaj6uzCegvUvKqvCFc2MNWk3nUbv-iTjbiAlhiXoXWj7ItHn7bXNNOuOu_uuGvSG8tPtlFLbBRVEPvD-etsnmBdaxWIA8_ujiz-XL1UhKujSm5JKtkTkE6H_nfS1K_snPn1VGzZzV6NFWPBxJtvvBGMJ5my5DJ_PfCZ9BW5-V-UNJ7vMqIEWR2GwE1YbZ5sHNsOcZZVj6D6Q9PaxnZqc3ZbMo7DWjI5vmb27rSsckFX3rOhAdlkxaQl6gaGNHxNW9Fe4Gh1fHp5w33SBFzIKGq6lG4tCxkZai-pukMmpMxhXBc6mNqU8qlHShRa3lrHJUeOjuEjHzmkMgEUu5DcYlFVpV4EpFWij0SI4m0dJYE2SojAkkQildrh1GkLQ0y8rPCI5NcaYZGEPQv43yYfw8_mXuw6O472Pt3umZKg0lAlBklVtnQmlQ3xEhGv43nHreTgZKykxEhzCDrEv6yXy7XnWPvzlOnwRdH1iVgy4AYPmvrWbGNQ0-RYK4sHRwWjLC-QT7LntBA |
| linkProvider | SAGE Publications |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS8MwFA4yQX0R785rBEEQIm2TJu2jiGPq5oNsuLeSdokIsx3r9qC_3nPWbOIVH_qWpuF8OZf0nPOFkFMe29iGkc_A-6UMDJ7HIikN60eZUqlUQvrYO9y-l82uuO2FPVdVib0wToLlBZZVwYqmxnqu3ciUxDlEJOBY8OTCQ-zdWxQhWOIaWbxsPDx2Pgo8pFdlKjlWXwXC5TR_nOSzV_oWan4q85p6nsYaWXUhI72sMF4nCybfIEttlxTfJE-tIn9iaGIp3oXFAFczoKW2ZvxKp_SxtLAUPAFI0bxNXnRKn3PqCFVLin9iqRk-lwVMSIsRzSq-XJoNJsiiQMFc95H2eYt0G9edqyZz9yewjAtvzBS3_SDjoebGgOZqwCu2GkIkz5rYxJgS1ZJb38ApMdQpKK8Is7hvrYJYNkgDvk1qeZGbXUKl9JRWoNzWpCLyjI5iwDUSgc-VhVNQnXgz-SWZIxfHOy4GiT_jE_8q8jo5n78yrJg1_hp8MgMlgf2PSQ0QWTEpk0AqH55AwBp2KrTm0_FQcg5BXZ2cIXzJbHP9_p29f488JsvNTruVtG7u7_bJSoBdEdMavwNSG48m5hBilXF65DblO0Sw2PI |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8QwEA6ygngR367PCIIgxG2bNGmPoi7rExFFbyVtk2VhbRe7e9Bf78w2q_jEQ29pEmYyr8zMF0L2eGxjG0Y-A-uXMlB4HoukNCyPMqVSqYT0sXf46lp27sX5Y_joLtywF8ZRsDrEsirY0VhZo3QPcttyOcaWxzl4JWBcMHrhIfbvTQsBQV6DTB-1bx_uPoo8pFdnKzlWYAXC5TV_nOSzZfrmbn4q9Rpbn_Y8mXNuIz2q-bxApkyxSGauXGJ8iXQvy6LLUM1SfA-LAW9Nn1bamuELHUPI0tJSsAZASfM6etIp7RXUgapWFG9jqRn0qhImpOUzzWrMXJr1R4ikQEFl5wj9vEzu26d3xx3m3lBgGRfekClu8yDjoebGgPRq4FlsNbhJnjWxiTEtqiW3voFIMdQpCLAIszi3VoE_G6QBXyGNoizMGqFSekorEHBrUhF5Rkcx8DYSgc-VhUioSbwJ_ZLMAYzjOxf9xJ9gin8leZMcvP8yqNE1_hq8O2FKAjKAiQ0gWTmqkkAqH75AwB5Wa269T8dDyTk4dk2yj-xLJgfs93XW_z1yh8zcnLSTy7Priw0yG2BjxLjMb5M0hs8jswXuyjDddmfyDcjo2gs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+open-label+safety+study+of+galcanezumab+in+patients+with+episodic+or+chronic+cluster+headache&rft.jtitle=Cephalalgia&rft.au=Riesenberg%2C+Robert&rft.au=Gaul%2C+Charly&rft.au=Stroud%2C+Chad+E&rft.au=Dong%2C+Yan&rft.date=2022-10-01&rft.eissn=1468-2982&rft.spage=3331024221103509&rft_id=info:doi/10.1177%2F03331024221103509&rft_id=info%3Apmid%2F35633025&rft.externalDocID=35633025 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0333-1024&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0333-1024&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0333-1024&client=summon |